drugset

drugset / Trial / NCT06583291

iDAP Injection in the Treatment of Parkinson's Disease

NCT06583291 ↗

Phase 0 Not yet recruiting 12 enrolled Anhui Provincial Hospital

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that iDAP has on Parkinson's disease (PD) patients.

Timeline

Start: 2024-10-01
Primary completion: 2028-10-01
Completion: 2028-10-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	iDAP	Cell therapy	—	Other

Indications